Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Sosei Group ( (JP:4565) ).
Nxera Pharma has proposed a reduction in capital reserve and disposition of surplus to offer greater flexibility for future shareholder returns. The planned financial restructuring will not impact the company’s net assets or business performance, as it involves internal title transfers within net assets.
More about Sosei Group
Nxera Pharma is a technology-driven biopharmaceutical company dedicated to developing new specialty medicines to address unmet medical needs in Japan and globally. The company has a robust pipeline of over 30 active programs spanning neurology, gastrointestinal and immunology, metabolic disorders, and rare diseases. Leveraging its advanced GPCR-targeted structure-based drug discovery platform, Nxera aims to deliver best- or first-in-class drug candidates.
YTD Price Performance: -1.29%
Average Trading Volume: 614
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $529.5M
For a thorough assessment of 4565 stock, go to TipRanks’ Stock Analysis page.
